{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:58:15Z","timestamp":1761976695948,"version":"build-2065373602"},"reference-count":11,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T00:00:00Z","timestamp":1383782400000},"content-version":"vor","delay-in-days":7250,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Anxiety"],"published-print":{"date-parts":[[1994,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>L\u2010365,260 is a CCK<jats:sub>B<\/jats:sub>antagonist which has been shown to completely prevent CCK\u20104\u2010induced symptoms of panic attack in single\u2010dose (50 mg) placebo\u2010controlled studies in patients with panic disorder. The present report is data from one site (n = 38) in a multicenter study (n = 88) designed to assess the preliminary efficacy and safely of L\u2010365,260 in patients meeting DSM\u2010III\u2010R criteria for panic disorder, with or without agoraphobia. In order to participate, male and female patients were between 18\u201355 years of age and in good physical health. Following a one\u2010week single\u2010blind placebo lead\u2010in, patients were randomized to 30 mg four times daily of L\u2010365,260 (n = 18; 7 M, 11 F) or placebo (n = 20; 9 M, 11 F) for six weeks. At end of study, none of the efficacy measures, including the frequency of panic attacks, the Physician's Global Improvement Scale, and the Hamilton Rating Scale for Anxiety, were significantly improved over baseline values. L\u2010365,260 was well\u2010tolerated the most common drug\u2010related adverse events were headache and lightheadedness. Further testing of L\u2010365,260 at higher dosages, or testing of other CCK<jats:sub>B<\/jats:sub>antagonists, is required to rule out the usefulness of this novel treatment approach. Anxiety 1:141\u2013143 (1994\/1995). \u00a9 1995 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/anxi.3070010308","type":"journal-article","created":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T12:05:16Z","timestamp":1383825916000},"page":"141-143","source":"Crossref","is-referenced-by-count":13,"title":["Pilot study of a CCK<sub>B<\/sub>antagonist in patients with panic disorder: Preliminary findings"],"prefix":"10.1002","volume":"1","author":[{"given":"J. J.","family":"Sramek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. S.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Reines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. R.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,11,7]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"763","article-title":"L\u2010365,260, a CCKB antagonist, blocks CCK\u20104 panic. Society for Neuroscience 22nd Annual Meeting, Anaheim, October 1992","volume":"18","author":"Bradwejn J","year":"1992","journal-title":"Soc Neurosci Abstr"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674379003500115"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810060031006"},{"key":"e_1_2_1_5_1","doi-asserted-by":"crossref","unstructured":"GuyW(1976)ECDEU Assessment Manual for Psychopharmacology U.S. Department of Health Education and Welfare. NIMH Publ. No. 76\u2013338 pp.217\u2013222.","DOI":"10.1037\/e591322011-001"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)91232-6"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8260.1967.tb00530.x"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1989.tb12637.x"},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-3565(25)12479-8","article-title":"Effects of protein binding and experimental disease states on brain uptake of benzodiazepines in rats","volume":"253","author":"Lin TH","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90290-2"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1985.tb07105.x"}],"container-title":["Anxiety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fanxi.3070010308","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/anxi.3070010308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T19:48:28Z","timestamp":1746042508000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/anxi.3070010308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,1]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1994,1]]}},"alternative-id":["10.1002\/anxi.3070010308"],"URL":"https:\/\/doi.org\/10.1002\/anxi.3070010308","archive":["Portico"],"relation":{},"ISSN":["1070-9797","1522-7154"],"issn-type":[{"type":"print","value":"1070-9797"},{"type":"electronic","value":"1522-7154"}],"subject":[],"published":{"date-parts":[[1994,1]]}}}